Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Kang, Jung Hun | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Park, Joon Oh | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Lee, Sang-Cheol | - |
dc.contributor.author | Park, Keon-Woo | - |
dc.contributor.author | Lee, Hyo Rak | - |
dc.contributor.author | Kang, Won Ki | - |
dc.date.accessioned | 2021-08-11T22:24:29Z | - |
dc.date.available | 2021-08-11T22:24:29Z | - |
dc.date.issued | 2014-11 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.issn | 1879-0852 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/11752 | - |
dc.description.abstract | Purpose: We aimed to the addition of synthetic 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin to capecitabine-cisplatin (XP) in patients with previously untreated advanced gastric cancer (AGC). Methods: In this double-blind, placebo-controlled, phase III study, we enrolled patients aged 18 years or older with histological or cytological confirmed metastatic adenocarcinoma of the stomach or gastroesophageal junction (GEJ) at nine centres in Korea. Patients, stratified by disease measurability and participating site, were randomly assigned (1:1) to receive capecitabine 1000 mg/m(2) twice daily for 14 days and cisplatin 80 mg/m(2) on day 1 every 3 weeks plus either simvastatin 40 mg or placebo, once daily. Cisplatin was given for 8 cycles; capecitabine and simvastatin were administered until disease progression or unacceptable toxicities. This study is registered with ClinicalTrials.gov, number NCT01099085. Results: Between February 2009 and November 2012, 244 patients were enrolled and assigned to treatment groups (120 simvastatin, 124 placebo). Median progression free survival (PFS) for 120 patients allocated XP plus simvastatin was 5.2 months (95% confidence interval (CI) 4.3-6.1) compared with 4.63 months (95% CI 3.5-5.7) for 124 patients who were allocated to XP plus placebo (hazard ratio 0.930, 95% CI 0.684-1.264; p = 0.642). 63 (52.5%) of 120 patients in simvastatin group and 70 (56.4%) of 124 had grade 3 or higher adverse events. Conclusions: Addition of 40 mg simvastatin to XP does not increase PFS in our trial, although it does not increase toxicity. Low dose of simvastatin (40 mg) to chemotherapy is not recommended in untargeted population with AGC. (c) 2014 Elsevier Ltd. All rights reserved. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.title | Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.ejca.2014.08.005 | - |
dc.identifier.scopusid | 2-s2.0-84924234737 | - |
dc.identifier.wosid | 000342701500009 | - |
dc.identifier.bibliographicCitation | European Journal of Cancer, v.50, no.16, pp 2822 - 2830 | - |
dc.citation.title | European Journal of Cancer | - |
dc.citation.volume | 50 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | 2822 | - |
dc.citation.endPage | 2830 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | CURATIVE RESECTION | - |
dc.subject.keywordPlus | MEVALONATE PATHWAY | - |
dc.subject.keywordPlus | INDUCED APOPTOSIS | - |
dc.subject.keywordPlus | II TRIAL | - |
dc.subject.keywordPlus | LOVASTATIN | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | STATINS | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | ATORVASTATIN | - |
dc.subject.keywordAuthor | Synthetic 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) | - |
dc.subject.keywordAuthor | Simvastatin | - |
dc.subject.keywordAuthor | Gastric cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.